Indrek Teino, Research Fellow, University of Tartu

Value of the Information & Strength of the Argument

The presentation provides significant value by presenting original data linking m6A levels to neuronal survival and a potential therapeutic strategy for Parkinson’s disease. The argumentation is solid: the speaker systematically demonstrates the effects of both inhibiting and activating METTL3, using multiple neuronal types, multiple inhibitors, and in vivo models. The mechanistic pathway from m6A reduction to TFEB-mediated autophagy and apoptosis is clearly delineated, and the rescue experiments with small molecules are convincing. The use of positive controls like GDNF and the dose-response relationships strengthen the claims. However, some conclusions are based on preliminary data (e.g., endogenous regulators) and the specificity of the compounds is not fully addressed. The speaker acknowledges limitations and future directions, which adds to the credibility.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high: the presentation includes controlled experiments, appropriate statistical measures (though not explicitly stated), and validation across different models. The speaker cites the METTL3 inhibitor STM2457 as published in Nature (2019), and mentions the clinical candidate SDC15. No external references are provided in the description, but the talk relies on the speaker’s own unpublished data and well-known literature. The title is simply the speaker’s name and affiliation, which is common for conference talks and does not reflect the content, but this is not a significant issue. The Q&A reveals the speaker’s honesty about uncertainties, such as the selectivity of m6A and non-catalytic functions of METTL3, which indicates a rigorous approach.

The title is just the speaker's name and affiliation, which is standard for conference talks but does not describe the content. It does not mislead, but is not informative.

8/10

The talk presents original research data from a conference presentation, including in vitro and in vivo experiments with clear methodology and controls. While some conclusions are preliminary and not yet peer-reviewed, the presentation is rigorous and transparent about limitations.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 01:00Introduction to m6A: definition, functions, and role in neurons
• 05:00Inhibition of METTL3 reduces m6A and induces neuronal death in multiple neuron types
• 09:00Mechanism: reduced m6A stabilizes TFEB mRNA, leading to autophagy and apoptosis
• 13:00Small molecule activators of METTL3 protect dopamine neurons in vitro and in vivo
• 17:00Mitochondrial support and conclusions; future plans for endogenous regulators

• STM2457 (METTL3 inhibitor) — Used to knock down m6A levels in neurons; mentioned as a specific inhibitor developed and published in 2019.
• SDC15 (clinical candidate) — Mentioned in Q&A as a successor to STM2457 in clinical trials for cancer.
• 6-Hydroxydopamine (6-OHDA) — Neurotoxin used to model Parkinson's disease in vitro and in vivo.
• GDNF (Glial cell-derived neurotrophic factor) — Positive control for neuroprotection in dopamine neuron survival assays.